1 / 6

THE VIEW FROM THE PUBLIC PARTNERS

THE VIEW FROM THE PUBLIC PARTNERS. Sheila Tunstall-James Chair of PAPIG. THE ROLE OF THE PUBLIC PARTNERS AT SMC :. Public Partners have been members of SMC since its inception in 2001 Public Partners are three independent lay members from diverse backgrounds

novia
Télécharger la présentation

THE VIEW FROM THE PUBLIC PARTNERS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. THE VIEW FROM THE PUBLIC PARTNERS Sheila Tunstall-James Chair of PAPIG

  2. THE ROLE OF THE PUBLIC PARTNERS AT SMC : • Public Partners have been members of SMC since its inception in 2001 • Public Partners are three independent lay members from diverse backgrounds • Equal partners with our clinical and economic expert colleagues • Bring a different perspective to the evaluation process • Act as advocates for Patient Interest Groups, patients and carers • Ensure that at every assessment the focus is the needs of patients and carers-including social, economic and quality of life issues

  3. PATIENT INTEREST GROUP ENGAGEMENT: • Survey by ScotCen during 2006/2007 • Participants expressed overall satisfaction with their interaction with SMC • Current process quite successful when understood • Limited awareness is a concern; • 41% knew of website • 33% knew of process for submissions • 66% cited lack of information when relevant medicines were due for assessment • More support, guidance and feedback needed

  4. INTERNAL EVALUATION OF IMPACT OF PAPIG : • October 2003 to December 2007, 117 Patient Interest Group submissions presented for 97 new medicines • 63% of those submissions supported by a Patient Interest Group were accepted or accepted with restrictions

  5. CHALLENGES FOR THE FUTURE • Increase knowledge for Patient Interest Groups of the SMC process • Timely information on when relevant medicines are to be assessed • Encourage more Patient Interest Group representatives to attend SMC meetings to observe the process • Increase support for Patient Interest Groups - especially the smaller ones

  6. PUBLIC PARTNER’S ACTION PLAN : • Implement Business Plan • Ensure Patient Interest Group database is current and comprehensive • Evaluate and update website information regularly • Provide training days for Patient Interest Groups • Appoint a dedicated Public Support Officer • Be open to suggestions of other ways to support patients, carers and their families in expressing their needs when new medicines are being considered by SMC for approval

More Related